drugset / Trial / NCT01904058

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

NCT01904058

Phase 2 Completed 66 enrolled Mirum Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is a randomized, double-blind, placebo-controlled, multicenter study. It is a 13-week Phase 2 study in adults with primary biliary cirrhosis designed to compare the effect of daily dosing with UDCA in combination with LUM001 or placebo.

Timeline

Start
2013-08
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule Oral
Background Ursodeoxycholic Acid Small molecule Oral